jueves, 1 de agosto de 2024
Mismanagement of Acute Decompensated Heart Failure with Hypertensive Emergency Jaenic Lee, MD, Josh Fernelius, MD and William Frick, MD | July 31, 2024
https://psnet.ahrq.gov/web-mm/mismanagement-acute-decompensated-heart-failure-hypertensive-emergency
Mismanagement of Acute Decompensated Heart Failure with Hypertensive Emergency
In this WebM&M Spotlight Case with CE/MOC, a 55-year-old woman with a history of panic attacks, obesity, and untreated hypertension experienced syncope after feeling flushed and lightheaded. On arrival at the emergency department, she had severely elevated blood pressure and hypoxemia. Diagnostic tests revealed acute heart failure exacerbation with pulmonary edema, marked elevation of brain natriuretic peptide (BNP), and elevated troponin-I. Despite treatment with diuretics and antihypertensives, her condition deteriorated, leading to intubation due to respiratory failure and subsequent cardiac arrest; cardiopulmonary resuscitation resulted in return of spontaneous circulation. However, she suffered from ischemic stroke and intracranial hemorrhages, ultimately leading to a transition to comfort care and subsequent death. The commentary discusses the contraindications for beta-blockers in the setting of acute decompensated heart failure and appropriate treatment for hypertensive emergencies in the emergency department and intensive care unit.
Evaluating Excipient Safety in Pediatric Populations: Current Thinking from a Bioequivalence Perspective August 8, 2024
https://www.fda.gov/drugs/news-events-human-drugs/evaluating-excipient-safety-pediatric-populations-current-thinking-bioequivalence-perspective?utm_medium=email&utm_source=govdelivery#event-information
This webinar is hosted by the Food and Drug Administration (FDA), in collaboration with the American Association of Pharmaceutical Scientists (AAPS) and will explore the latest thinking and practices in evaluating excipient safety for pediatric populations, with a focus on bioequivalence assessment for generic drugs. Join our expert speakers as they:
Share the latest developments in excipient safety evaluation for pediatric populations,
Discuss the critical role of risk-based approaches in bioequivalence assessment, and
Present real-world case studies highlighting challenges and opportunities in ensuring excipient safety
By attending, you'll gain valuable insights and practical takeaways to enhance your work in ensuring the safety and well-being of pediatric patients.
FDA and CTTI to host a public workshop on AI in drug & biological product development 6 ago 2024 11:00 a. m.
https://duke.zoom.us/webinar/register/WN_YisPhfadR7iWGHfxhF8TOg?_x_zm_rtaid=juhZmvbmRfuZNxOYMg7JPA.1722521730813.f70a1b1d91b25aae69c078170f0f65dd&_x_zm_rhtaid=820#/registration
On Tuesday August 6, 2024 from 10 AM to 5:30 PM EDT, FDA and the Clinical Trials Transformation Initiative are hosting a free hybrid public workshop on artificial intelligence (AI) in drug and biological product development.
Please join us as we explore the guiding principles being applied by innovators and regulators to ensure AI is used responsibly. AI holds great potential to transform how drugs are developed, manufactured, and used.
Participants may attend virtually or in-person in the FDA Great Room located at 10903 New Hampshire Avenue, Silver Spring, MD 20993.
AHRQ Papers on Diagnostic Safety Topics
AHRQ Papers on Diagnostic Safety Topics: Diagnostic errors occur in all settings of care, contribute to about 10 percent of patient deaths, and are the primary reason for medical liability claims. AHRQ is the lead Federal agency investing in research to improve diagnostic safety and reduce diagnostic error. AHRQ is currently developing a series of papers on different diagnostic safety issues, which will be released over the next year.
How NIMH’s Disparities Research Priorities Inform Suicide Prevention Efforts Beshaun Davis, Ph.D., and Stacia Friedman-Hill, Ph.D., on behalf of the NIMH Office of Disparities Research and Workforce Diversity and the NIMH Disparities Team
https://www.nimh.nih.gov/about/director/messages/2024/how-nimhs-disparities-research-priorities-inform-suicide-prevention-efforts?utm_campaign=MMHM24&utm_medium=email&utm_source=govd
As July ends, let's continue to honor Minority Mental Health Awareness Month by reflecting on the National Institute of Mental Health's (NIMH) dedication to mental health equity. The Office of Disparities Research and Workforce Diversity and the Disparities Team are leading the charge in addressing mental health disparities and enhancing suicide prevention for underserved communities.
Together with all of NIMH, we’re making strides in research and interventions to save lives and improve outcomes. Learn more about our efforts and how we’re advancing equity in mental health.
Suscribirse a:
Entradas (Atom)
